Core Viewpoint - Keros Therapeutics, Inc. is under investigation for potential securities fraud and unlawful business practices following significant stock price declines related to safety concerns in its clinical trials [1][2][3]. Group 1: Company Actions and Stock Performance - On December 12, 2024, Keros announced a voluntary halt in dosing for certain treatment arms in the TROPOS trial due to safety concerns, resulting in a stock price drop of $50.22 per share, or 73.15%, closing at $18.43 [2]. - On January 15, 2025, Keros further halted all dosing in the TROPOS trial based on ongoing safety reviews, leading to an additional stock price decline of $2.06 per share, or 16.51%, closing at $10.42 [3]. Group 2: Legal Investigation - Pomerantz LLP is investigating claims on behalf of Keros investors regarding potential securities fraud or other unlawful practices by the company and its officers or directors [1].

Core Insights - Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapeutics targeting disorders linked to dysfunctional signaling of the TGF-ß protein family [1][3] - The company will participate in a fireside chat at the Guggenheim SMID Cap Biotech Conference on February 6, 2025 [1] Company Overview - Keros Therapeutics is recognized for its expertise in the TGF-ß protein family, which regulates growth, repair, and maintenance of various tissues including blood, bone, skeletal muscle, adipose, and heart tissue [3] - The company is developing several product candidates: - Cibotercept (KER-012) for pulmonary arterial hypertension and cardiovascular disorders [3] - KER-065 for neuromuscular diseases [3] - Elritercept (KER-050) for treating low blood cell counts, including anemia and thrombocytopenia, in patients with myelodysplastic syndrome and myelofibrosis [3]

Keros Therapeutics Stock Performance - Keros Therapeutics (KROS) shares have plunged 80.9% in the past three months and 79.8% over the past year, significantly underperforming the industry's 12% decline [1][4] Cibotercept (KER-012) Clinical Trial Update - The company voluntarily halted dosing in the mid-stage TROPOS study of cibotercept (KER-012) for pulmonary arterial hypertension (PAH) due to unexpected adverse pericardial effusion events [1][2] - Initially suspended dosing in the 3 mg/kg and 4.5 mg/kg treatment arms, later extended to include the 1.5 mg/kg and placebo arms [3] - The TROPOS study is being concluded ahead of schedule, with top-line data expected in Q2 2025 [5] Other Pipeline Candidates - Elritercept (KER-050) is in two ongoing phase II studies for myelodysplastic syndromes (MDS) and myelofibrosis, with a planned phase III RENEW study for transfusion-dependent anemia [8][9] - KER-065 is in phase I development for obesity and neuromuscular diseases, with top-line data expected in Q1 2025 and a proof-of-concept study planned in obese patients [10] Industry Comparison - Castle Biosciences (CSTL) shares have declined 16.3% in three months, with 2024 earnings estimates increasing from 34 to 39 cents per share [12] - BioMarin Pharmaceutical (BMRN) shares have lost 11.9% in three months, with 2024 earnings estimates improving from $3.28 to $3.29 per share [13] - CytomX Therapeutics (CTMX) shares have declined 22.4% in three months, with 2024 loss estimates remaining at 5 cents per share [14]

Company Overview - Keros Therapeutics, Inc. (KROS) shares increased by 5.1% to close at $11.41, following a significant trading volume compared to normal sessions, despite a 36.6% loss over the past four weeks [1] Recent Developments - The global development and commercialization license agreement with Takeda for elritercept became effective on January 16, 2025, with Takeda set to make an upfront payment of $200 million to Keros Therapeutics, potentially contributing to the recent share price rally [2] Financial Expectations - Keros Therapeutics is expected to report a quarterly loss of $0.93 per share, reflecting a year-over-year increase of 30.6%, while revenues are projected to be $105.25 million, a substantial increase of 75078.6% from the same quarter last year [3] - The consensus EPS estimate for the quarter has been revised 2.7% higher in the last 30 days, indicating a positive trend that may lead to price appreciation [4] Industry Context - Keros Therapeutics operates within the Zacks Medical - Biomedical and Genetics industry, where another company, Revolution Medicines, Inc. (RVMD), experienced a 0.3% decline to $40.16, with a return of -8.3% over the past month [4]

Core Viewpoint - Keros Therapeutics, Inc. is under investigation for potential securities fraud and unlawful business practices following significant stock price declines related to safety concerns in its clinical trials [1][2][3]. Group 1: Company Actions and Stock Performance - On December 12, 2024, Keros announced a voluntary halt in dosing for certain treatment arms in the TROPOS trial due to safety concerns, leading to a stock price drop of $50.22 per share, or 73.15%, closing at $18.43 [2]. - On January 15, 2025, Keros further halted all dosing in the TROPOS trial based on ongoing safety reviews, resulting in an additional stock price decline of $2.06 per share, or 16.51%, closing at $10.42 [3]. Group 2: Legal Investigation - Pomerantz LLP is investigating claims on behalf of Keros investors regarding potential securities fraud or other unlawful business practices by the company and its officers or directors [1].

Core Viewpoint - The article discusses an ongoing investigation related to Keros Therapeutics, Inc. (KROS) and highlights potential financial losses incurred by investors due to the company's actions [1] Group 1 - The investigation is being conducted by Levi & Korsinsky, focusing on whether Keros Therapeutics misled investors regarding its financial performance and business prospects [1] - Investors who have lost money on Keros Therapeutics are encouraged to contact the law firm for assistance in the investigation [1] - The article emphasizes the importance of understanding the implications of the investigation for current and potential investors in Keros Therapeutics [1]

Core Viewpoint - Keros Therapeutics, Inc. (KROS) is currently under investigation by Bronstein, Gewirtz & Grossman, LLC, which is encouraging stockholders to reach out for more information regarding the investigation [1] Group 1 - The investigation pertains to potential violations of securities laws by Keros Therapeutics [1] - Stockholders are being urged to contact the firm to understand the implications of the investigation [1] - The investigation may impact the stock performance and investor sentiment towards Keros Therapeutics [1]

LEXINGTON, Mass., Jan. 21, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros" or the "Company") (NASDAQ:KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta ("TGF-ß") family of proteins, today announced that the global development and commercialization license agreement with Takeda (NYSE:TAK) to advance elritercep ...

Shareholders that lost money on Keros Therapeutics, Inc. (KROS) should contact Levi & Korsinsky about Securities Fraud Investigation - KROS ...

A downtrend has been apparent in Keros Therapeutics, Inc. (KROS) lately with too much selling pressure. The stock has declined 36.2% over the past four weeks. However, given the fact that it is now in oversold territory and Wall Street analysts are majorly in agreement about the company's ability to report better earnings than they predicted earlier, the stock could be due for a turnaround.Guide to Identifying Oversold StocksWe use Relative Strength Index (RSI), one of the most commonly used technical indic ...